EFFECTIVENESS OF APPLICATION OF COMBINED THERAPY OF EARLY ERYTHEMA STAGE OF LYME DISEASE TAKING INTO CONSIDERATION IMMUNOGENESIS FEATURES

Aim. Study innate and adaptive immunity in patients with migrating erythema, clinical effectiveness of combined therapy using Immunovac vaccine and dynamics of immunologic parameters as a result of the therapy. Materials and methods. 37 adult patients with migrating erythema were examined. The patients were divided into 2 groups: 1st gr. (14 individuals) - Immunovac by intranasal-subcutaneous method against the background of basic therapy; 2nd gr. (23 individuals) - 200 mg/day doxycycline therapy for 21 days. Phagocytic activity of blood neutrophils; TLRs expression on mononuclear leukocytes of peripheral blood (PBML) and skin cells in foci by flow cytometry with mAT against TLR2, 3,4, 5,6, 7, 8,9 using flow cytometer FC-500; subpopulation composition of peripheral blood lymphocytes; levels of pro-, anti-inflammation and regulatory cytokines in blood sera by EIA method; IgG, IgM, IgA in blood sera were studied in patients before treatment and 1 month after therapy. Results. A high level of TLR2, 4, 7, 8 on skin cells in foci, TLR2, 4 - on blood cells; low content of CD95+ and CD25+, high level of serum IF-lb, IL-2 and IF-4, an increase of general IgE level was detected in patients with migrating erythema. Immunovac facilitated an increase of CD95+ and CD25+, IFN-y synthesis, reduced the level of general IgE in a more pronounced way than basic therapy. Conclusion. Inclusion of Immunovac into therapy of patients with migrating erythema facilitates increase of clinical effectiveness and correlates with correction of immunologic disorders.

Toll-подобные рецепторы, migrating erythema, Toll-like receptors, Immunovac vaccine